Suppression of matrix metalloproteinase production from nasal fibroblasts by fluticasone propionate in vitro

Acta Oto-Laryngologica

Volumn 124, Issue 8, 2004, Pages 964-969

  Namba, Mayumi ^a   Asano, Kazuhito ^a   Kanai, Ken Ichi ^a   Kyo, Yoshiyuki ^a   Watanabe, So ^a   Hisamitsu, Tadashi ^a   Suzaki, Harumi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Fibroblast; Fluticasone propionate; In vitro; Matrix metalloproteinase; Nasal polyp; Suppression

Indexed keywords

FLUTICASONE PROPIONATE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; FEMALE; FIBROBLAST CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NOSE POLYP; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NASAL POLYPS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 5644275254     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480310016947     Document Type: Article

References (21)

1. Kramer MF, Rasp G. Nasal polyposis: eosinophils and interleukin-5. Allergy 1999; 54: 669-80.
2. Settipane GA. Epidemiology of nasal polyps. Allergy Asthma Proc 1996; 17: 231-6.
3. Norlander T, Westrin KM, Fukami M, Stierna P, Carlsoo B. Experimentally induced polyps in the sinus mucosa: a structural analysis of the initial stages. Laryngoscope 1996; 106: 196-203.
4. Powers MR, Qu Z, LaGesse PC, Liebler JM, Wall MA, Rosenbaum JT. Expression of basic fibroblast growth factor in nasal polyps. Ann Otol Rhinol Laryngol 1998; 107: 891-7.
5. Nonaka M, Pawankar R, Saji F, Yagi T. Effect of roxithromycin on IL-8 synthesis and proliferation of nasal polyp fibroblasts. Acta Otolaryngol Suppl (Stockh) 1998; 539: 71-5.
6. Lechapt-Zalcman E, Coste A, d'Ortho MP, Frisdal E, Harf A, Lafuma C, Escudier E. Increased expression of matrix metalloproteinase-9 in nasal polyps. J Pathol 2001; 193: 233-41.
7. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996; 148: 1345-50.
8. Herouy Y, Mellios P, Bandemir E, Dichmann S, Nockowski P, Schopf E. Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression. J Dermatol Sci 2001; 25: 198-205.
9. Ohno I, Ohtani H, Nitta Y, Suzuki J, Hoshi H, Honma M. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997; 16: 212-9.
10. Hoshino M, Nakamura Y, Sim J, Shimojo J, Isogai S. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 1998; 102: 783-8.
11. Mygind N, Naclerio RM. Intranasal corticosteroids. In: Naclerio RM, Durham SR, Mygind N, eds. Rhinitis: mechanisms and management. New York: Marcel Dekker; 1999. p. 221-65.
12. Bolard F, Gosset P, Lamblin C, Bergoin C, Tonnel AB, Wallaert B. Cell and cytokine profiles in nasal secretions from patients with nasal polyposis: effects of topical steroids and surgical treatment. Allergy 2001; 56: 333-8.
13. Cataldo DD, Tournoy KG, Vermaelen K, Munaut C, Foidart JM, Louis R. Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation. Am J Pathol 2002; 161: 491-8.
14. Forsgren K, Fukami S. Endoscopie and Caldwell-Luc approaches in chronic maxillary sinusitis: a comparable histopathologic study on preoperative and postoperative mucosal morphology. Ann Otol Rhinol Laryngol 1995; 104: 350-7.
15. Al-Rawi MM, Edelstein DR, Erlandson RA. Changes in nasal epithelium in patients with severe chronic sinusitis: a clinicopathologic and electron microscopic study. Laryngoscope 1998; 108: 1816-23.
16. Majima Y, Masuda S, Sakakura Y. Quantitative study of nasal secretory cells in normal subjects and patients with chronic sinusitis. Laryngoscope 1997; 107: 1515-8.
17. Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity allergen challenge, and inhaled corticosteroids. Chest 2002; 122: 1543-52.
18. Bosse M, Chakir J, Rouabhia M, Boulet LP, Audette M, Laviolette M. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999; 159: 596-602.
19. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
20. Burnstein KL, Cidlowski JA. At the cutting edge: the down side of glucocorticoid receptor regulation. Mol Cell Endocrinol 1992; 83: C1-8.
21. Knutsson PU, Bronnegard M, Marcus C, Stierna P. Regulation of glucocorticoid receptor mRNA in nasal mucosa by local administration of fluticasone and budesonide. J Allergy Clin Immunol 1996; 97: 655-61.